Metabolisches Syndrom - Quo vadis et cui bono?

Zusammenfassung

Das metabolische Syndrom wird im Alter über 40 Jahren bei 25 - 30 % der deutschen Bevölkerung gefunden. Auf dem Konzept des metabolischen Syndroms aufbauend wird eine ganzheitliche Diagnostik und Therapie eines Bündels von Krankheiten möglich. Die Prävention des metabolischen Syndroms ist essentiell für die Verhinderung eines weiteren Anstiegs der Prävalenz von Typ-2-Diabetes und koronarer Herzkrankheit. Aufbauend auf dem „common soil” für die Krankheiten des metabolischen Syndroms können die Therapie optimiert sowieNebenwirkungen und Kosten gesenkt werden.

Summary

The metabolic syndrome is found in 25 - 30 % of the german population over the age of 40 years. The concept of metabolic syndrome makes possible an all-inclusive diagnosis and treatment of a bundle of diseases. Prevention of this syndrome is essential if a further rise in the incidence of type 2 diabetes mellitus and coronary heart disease is to be prevented. Building on a „common soil” for the disease components, optimal treatment can be provided and side effect as well as costs reduced.

Literatur

• 1 Hanefeld M, Leonhardt W. Das metabolische Syndrom.  Dtsch Gesundheitsw. 1981;  36 545-551
• 2 Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
• 3 Alberti K G, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a Who consultation. Expert panel on detection, evaluation, and treatment of high blood pressure in adults.  Diabet Med. 1998;  15 539-553
• 4 Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III). 
• 5 Grundy S M, Cleeman J I, Daniels S R. et al . Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lund, and Blood Institute Scientific Statement. Executive Summary.  Circulation. 2005;  112 2735-2752
• 6 International Diabetes Federation .The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/Metac_Syndrome_def.pdf 2005
• 7 Alexander C M, Landsman P B, Teutsch S M, Haffner S M. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP) . NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older.  Diabetes. 2003;  52 1210-1214
• 8 Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetologia. 2005;  48 1684-1699
• 9 Knowler W C, Barrett-Connor E, Fowler S E. et al.; Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 10 Tuomilehto J, Lindstrom J, Eriksson J G. et al.; Finnish Diabetes Prevention Study Group . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
• 11 Rubio M A, BallesterosPomar M D, Moreno C. Nutritional treatment in the metabolic syndrome. Elsevier, Madrid In: Serrano Rios M, Caro JF, Carraro R, Gutierrez Fuentes JA. The Metabolic Syndrome at the beginning of the XXIst century - a genetic and molecular approach 2005: 415-431
• 12 Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome.  Arterioscler Thromb Vasc Biol. 2004;  24 29-33
• 13 Torgerson J S, Hauptman J, Boldrin M N, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.  Diabetes Care. 2004;  27 155-161 , Erratum in: Diabetes Care 2004; 27: 856.
• 14 Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M. for the STOP-NIDDM Trial Research Group . Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance.  JAMA. 2003;  290 486-494
• 15 Abuissa H, Jones P G, Marso S P, O’Keefe J H. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes.  J Am Coll Cardiol. 2005;  46 821-826
• 16 Lindholm L H, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.  Lancet. 2005;  366 1545-1553